Who
Garrett Winslow
General Counsel
Company insider
Files Form 4 as: General Counsel, Damora Therapeutics; General Counsel and Secretary, F-star Therapeutics.
In numbers
- Trades disclosed
- 34
- Buys
- 2
- Sells
- 5
- Bought
- $15K
- Sold
- $30K
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 5 Mar 2020
- Last trade
- 6 Jul 2026
- Last filed
- 7 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 6 Jul 2026filed 7 Jul 2026 | DMRA Damora TherapeuticsBiotechnology | SEC FORM 4 Sold | $7,345245 at $29.98 | filing |
| 6 Jul 2026filed 7 Jul 2026 | DMRA Damora TherapeuticsBiotechnology | SEC FORM 4 Sold | $7,345245 at $29.98 | filing |
| 3 Jul 2026filed 7 Jul 2026 | DMRA Damora TherapeuticsBiotechnology | SEC FORM 4 Code M | —680 | filing |
| 3 Jul 2026filed 7 Jul 2026 | DMRA Damora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —680 at $0.00 | filing |
| 3 Jul 2026filed 7 Jul 2026 | DMRA Damora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —680 at $0.00 | filing |
| 3 Jul 2026filed 7 Jul 2026 | DMRA Damora TherapeuticsBiotechnology | SEC FORM 4 Code M | —680 | filing |
| 23 Mar 2026filed 25 Mar 2026 | DMRA Damora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —250,000 at $0.00 | filing |
| 23 Mar 2026filed 25 Mar 2026 | DMRA Damora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —250,000 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | GalectoBiotechnology | SEC FORM 4 Code M | —680 | filing |
| 2 Jan 2026filed 6 Jan 2026 | GalectoBiotechnology | SEC FORM 4 Sold | $5,452255 at $21.38 | filing |
| 2 Jan 2026filed 6 Jan 2026 | Galectooption or derivative · Biotechnology | SEC FORM 4 Code M | —680 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | DMRA Damora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —680 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | DMRA Damora TherapeuticsBiotechnology | SEC FORM 4 Code M | —680 | filing |
| 2 Jan 2026filed 6 Jan 2026 | DMRA Damora TherapeuticsBiotechnology | SEC FORM 4 Sold | $5,452255 at $21.38 | filing |
| 3 Jul 2025filed 8 Jul 2025 | DMRA Damora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —680 at $0.00 | filing |
| 3 Jul 2025filed 8 Jul 2025 | DMRA Damora TherapeuticsBiotechnology | SEC FORM 4 Code M | —680 | filing |
| 3 Jul 2025filed 8 Jul 2025 | DMRA Damora TherapeuticsBiotechnology | SEC FORM 4 Sold | $881260 at $3.39 | filing |
| 3 Jan 2025filed 7 Jan 2025 | DMRA Damora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,320 at $0.00 | filing |
| 3 Jan 2025filed 7 Jan 2025 | DMRA Damora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,000 at $0.00 | filing |
| 3 Jan 2025filed 7 Jan 2025 | DMRA Damora TherapeuticsBiotechnology | SEC FORM 4 Code M | —1,320 | filing |
News
No headline names them, or the companies they trade most, lately.